In its comments to CMS on the final Medicare Access and CHIP Reauthorization Act (MACRA) rule, the American Medical Group Association asked the agency to limit the transition to new payment tracks to only one year and develop a new two-sided risk model in the Medicare Shared Savings Program (MSSP).

Groups with data-use agreements with HHS and CMS are scrambling to copy healthcare data and documents in case President-elect Donald Trump’s administration erases it once in office—a fear Trump-aligned groups call “paranoid.”

CMS hopes to strengthen the risk pool on Affordable Care Act’s insurance marketplace for the 2018 plan year, even as insurers remain uncertain about the exchanges with the incoming Congress and President-elect promising to repeal the law.

The annual health issues report from PricewaterhouseCooper’s (PwC) Health Research Institute predicted the coming year will be one of “uncertainty and opportunity” in the industry, both because of the potential repeal of the Affordable Care Act and the continuing transition to value-based care.

Mylan announced the launch of the authorized generic of its allergic reaction autoinjector treatment, EpiPen. Although the launch fulfilled a promise the pharmaceutical company made months ago, it came only hours after 20 states filed a lawsuit over Mylan’s pricing of other generic drugs. 

Repealing the Affordable Care Act (ACA) can be passed with only Republican votes soon after President-elect Donald Trump takes office. Replacing the law, however, can’t be done by one party.

A report on the “economic record” of the Obama Administration’s healthcare reforms credited the Affordable Care Act (ACA) for lower uninsured rates, increased access to care and slowed growth in healthcare spending.

HHS Secretary Sylvia Burwell defended the Affordable Care Act (ACA) and the broader efforts of changing healthcare payments, delivery systems and health IT in a Health Affairs blog post.